In May the US FDA has issued five Warning Letters that address cGMP-violations on a large scale. The drug facilities involved are:

  • Jilin Shulan Synthetic Pharmaceutical und Nox Bellcow Cosmetics Co, China
  • Jalco Cosmetics, Australia
  • Europharma Concepts, Ireland
  • Reine Lifescience, India.

Read more